ARTICLE | Company News
AlphaVax, Novartis deal
January 5, 2009 8:00 AM UTC
AlphaVax granted Novartis exclusive, worldwide rights to develop and commercialize CMV alphavaccine ( AVX601) to prevent cytomegalovirus (CMV) infection. AlphaVax will receive $20 million up front an...